Clinical Trial Update: Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

View source ↗

Summary

A clinical trial update describing an investigation into recurrence mechanisms of adjuvant osimertinib in patients with radically resected EGFR-mutated non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: EGFR-mutated NSCLC | Status: RECRUITING